Classical transgenic and gene-targeted mouse mutants are powerful model systems in which to study the pathogenesis of neurodegenerative diseases. However, a number of issues of fundamental importance to neurodegenerative research cannot be addressed using classical techniques. These include identification of the earliest events in disease pathogenesis and a determination of whether a particular pathogenic protein produces a inexorable or a reversible disease process. Both of these issues have profound implications for the rational development of new therapies. To address these questions, genetic techniques that allow pathogenic proteins to be expressed or knocked out with temporal and regional specificity have been developed. We have reviewed these systems, highlighting the tetracycline-regulated system because of its demonstrated utility in mice and its reversibility. These regulatable systems are a new and powerful tool for the neurobiologist and allow one to address a new set of important questions in an in vivo setting.
INTRODUCTION
Genetically altered mice are powerful model systems in which to study the pathogenesis of neurodegenerative disease. The identification of pathogenic mutations underlying a number of these diseases has allowed investigators to create transgenic mouse models, and their characterization has given us insights into the role of the pathogenic proteins in these disorders (Dawson, 2000; Gurney, 2000; Janus et al., 2000; Sommer et al., 2000) . Despite these advances, however, mice made with traditional transgenic techniques are not ideally suited to address many questions of fundamental importance in neurodegenerative research. For example, classical transgenic mice do not allow the identification of the earliest events in disease pathogenesis. Furthermore, constitutively active promoters cannot address whether the progressive nature of these diseases requires continuous expression of the mutant protein, or allow one to determine if the pathogenic protein leads to a reversible or irreversible disease process. These types of questions can only be addressed in a system in which the expression of the pathogenic protein can be turned on or off at defined times.
To address these issues, regulatable promoters have been designed to allow precise control over transgene expression. In this review, we will discuss the most recent advances made in inducible technology and provide a brief summary of how they have been applied in transgenic mice.
EUKARYOTIC-BASED INDUCIBLE SYSTEMS
Regulatable mammalian systems have been designed around the heat shock, metallothionein, interferon-␥, and hormone-dependent promoters. However, their use has mostly been limited to cell culture and has met with little success in mice due to pleio-
